Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2015, Article ID 736092, 3 pages
http://dx.doi.org/10.1155/2015/736092
Case Report

Nilotinib-Associated Destructive Thyroiditis

Division of Endocrinology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY 10595, USA

Received 22 January 2015; Revised 16 April 2015; Accepted 16 April 2015

Academic Editor: Suat Simsek

Copyright © 2015 Suhalia Bakerywala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Weisberg, P. W. Manley, S. W. Cowan-Jacob, A. Hochhaus, and J. D. Griffin, “Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia,” Nature Reviews Cancer, vol. 7, no. 5, pp. 345–356, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Illouz, S. Laboureau-Soares, S. Dubois, V. Rohmer, and P. Rodien, “Tyrosine kinase inhibitors and modifications of thyroid function tests: a review,” European Journal of Endocrinology, vol. 160, no. 3, pp. 331–336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Makita and T. Iiri, “Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis,” Thyroid, vol. 23, no. 2, pp. 151–159, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. D. S. Krause and R. A. van Etten, “Tyrosine kinases as targets for cancer therapy,” The New England Journal of Medicine, vol. 353, no. 2, pp. 172–187, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Morabito, E. de Maio, M. Di Maio, N. Normanno, and F. Perrone, “Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions,” The Oncologist, vol. 11, no. 7, pp. 753–764, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Mannavola, P. Coco, G. Vannucchi et al., “A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 9, pp. 3531–3534, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. L. Vetter, S. Kaul, and N. Iqbal, “Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target,” Endocrine Practice, vol. 14, no. 5, pp. 618–624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. T. D. Kim, M. Schwarz, H. Nogai et al., “Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in philadelphia chromosome-positive chronic myeloid leukemia,” Thyroid, vol. 20, no. 11, pp. 1209–1214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Torino, S. M. Corsello, R. Longo, A. Barnabei, and G. Gasparini, “Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy,” Nature Reviews Clinical Oncology, vol. 6, no. 4, pp. 219–228, 2009. View at Publisher · View at Google Scholar
  10. R. M. Tuttle, R. Haddad, D. W. Ball et al., “NCCN clinical practice guidelines in oncology: thyroid carcinoma,” Journal of the National Comprehensive Cancer Network, vol. 12, no. 12, pp. 1671–1680, 2014. View at Google Scholar
  11. M. S. Brose, C. M. Nutting, B. Jarzab et al., “Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial,” The Lancet, vol. 384, no. 9940, pp. 319–328, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. E. N. Klein Hesselink, D. Steenvoorden, E. Kapiteijn et al., “Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis,” European Journal of Endocrinology, vol. 172, no. 5, pp. R215–R225, 2015. View at Publisher · View at Google Scholar
  13. A. A. Mohammed and A. El-Shentenawy, “Advanced thyroid cancers: new era of treatment,” Medical Oncology, vol. 31, no. 7, article 49, 2014. View at Google Scholar